Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 57   

Articles published

ARNA 4.47 -0.17 (-3.66%)
price chart
CEO of the Year, Round 2: Arena Pharmaceuticals vs. Regions Financial
On one hand, Arena Pharmaceuticals' Jack Lief is an innovator who's led his company to develop what could very well become the first internationally approved anti-obesity drug in Belviq.
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Vivus Or Arena: Who Has The Edge?
Two of the three major players in the treatment of obesity, VIVUS Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) released their financial results and provided an update on recent developments.
CEO of the Year: Apple vs. Arena Pharmaceuticals
Following eight straight weeks of profiling top-notch CEOs, the time has officially come for you and other members of The Motley Fool community to decide who is the best CEO in 2012.
Vivus, Arena shares jump on insurance coverage for diet pills
Health insurer Aetna Inc (AET.N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up. The decision by the third-largest health insurer to provide coverage ...
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Arena Pharma Sinks Under Weight Of Vivus' Troubles
The headline says it all, Arena Pharma Is Still A Good Short. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein.
Indian board rejects AstraZeneca's patent plea on cancer drug
Natco and another domestic drugmaker, G. M. Pharma, had opposed the initial patent application for AstraZeneca quinazoline derivative.
Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)
Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the October 15 and October 31 settlement dates.
FSD Drugs Advance as Women Push for Equal Access
In July, investors raised $20 million for startup Sprout Pharmaceuticals, which hopes to succeed where Boehringer Ingelheim failed by bringing flibanserin through development phases to market.
New drugs extend myeloma patients' lives
A wave of new treatments for patients with multiple myeloma, a deadly blood cancer, has doubled survival rates over the past decade from an average of three years at the time of diagnosis to more than seven years.